

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

1(currently amended). A metered dose inhaler which comprises a canister fitted with a metering valve which contains a pharmaceutical solution aerosol formulation which comprises:

- (i) fluticasone propionate and
- (ii) a hydrofluoroalkane (HFA) propellant,

characterised in that the fluticasone propionate is completely dissolved in the formulation; wherein the canister is fitted into a channelling device which comprises a mouthpiece actuator having an actuator exit orifice of diameter 0.25mm or less.

2(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 1 wherein the formulation which comprises:

- (i) fluticasone propionate;
- (ii) a hydrofluoroalkane (HFA) propellant;
- (iii) a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of an inhaler; and
- (iv) a solubilisation agent in sufficient quantity to solubilise the fluticasone propionate in the formulation.

3(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 1 wherein the hydrofluoroalkane (HFA) propellant is 1,1,1,2-tetrafluoroethane (HFA134a).

4(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 1 wherein the formulation contains containing a low volatility component which is glycerol, propylene glycol or polyethylene glycol.

5(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 4 wherein the formulation contains containing a low volatility component which is polyethylene glycol.

6(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 4 wherein the formulation contains containing a low volatility component which is glycerol.

7(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 4 wherein the formulation contains containing a low volatility component is present in the formulation at a concentration of 0.5 to 3% w/w.

8(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 1 wherein the formulation which comprises:

- (i) fluticasone propionate;
- (ii) 1,1,1,2-tetrafuoroethane (HFA 134a);
- (iii) 0.5-3% (w/w) glycerol; and
- (iv) a solubilisation agent in sufficient quantity to solubilise the fluticasone propionate in the formulation.

9(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 1, wherein the formulation which contains between 0.8 and 1.6% (w/w) glycerol.

10(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 9 wherein the formulation which contains between 1.0 and 1.6% (w/w) glycerol.

11(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 10 wherein the formulation which contains between 1.0 and 1.6% (w/w) glycerol.

12(currently amended). A metered dose inhaler pharmaceutical formulation according to claim 10 wherein the formulation which contains 1.0% (w/w) glycerol.

13(currently amended). A metered dose inhaler formulation according to claim 1 wherein the concentration of fluticasone propionate in the formulation is 0.025 to 0.15% w/v.

14(currently amended). A metered dose inhaler formulation according to claim 13 wherein the concentration of fluticasone propionate in the formulation is 0.035 to 0.15% w/v.

15(currently amended). A metered dose inhaler formulation according to claim 14 wherein the concentration of fluticasone propionate in the formulation is 0.04 to 0.1% w/v.

16(currently amended). A metered dose inhaler formulation according to claim 13 wherein the concentration of fluticasone propionate in the formulation is 0.025 to 0.04% w/v.

17(currently amended). A metered dose inhaler formulation according to claim 1 wherein a solubilisation agent is present in the formulation which is ethanol or propylene glycol.

18(currently amended). A metered dose inhaler formulation according to claim 1 wherein a solubilisation agent is present in the formulation which is an alkane or ether.

19(currently amended). A metered dose inhaler formulation according to claim 1 wherein a solubilisation agent is present in the formulation which is dimethoxymethane.

20(currently amended). A metered dose inhaler formulation according to claim 1 wherein a solubilisation agent is present in the formulation which is ethylacetate.

21(currently amended). A metered dose inhaler formulation according to claim 17 wherein a solubilisation agent is present in the formulation which is ethanol.

22(currently amended). A metered dose inhaler formulation according to claim 21 wherein the concentration of ethanol in the formulation is 5 to 30% w/w.

23(currently amended). A metered dose inhaler formulation according to claim 22 wherein the concentration of ethanol in the formulation is 10 to 20% w/w.

24(currently amended). A metered dose inhaler formulation according to claim 22 wherein the concentration of ethanol in the formulation is 7 to 16% w/w.

25(currently amended). A metered dose inhaler formulation according to claim 22 wherein the concentration of ethanol in the formulation is 7 to 11% w/w.

26(currently amended). A metered dose inhaler formulation according to claim 22 wherein the concentration of ethanol in the formulation is 7 to 8% w/w.

27(currently amended). A metered dose inhaler formulation according to claim 19 wherein the concentration of solubilisation agent in the formulation is 14 to 16% w/w.

Claim 28(canceled).

29(currently amended). A metered dose inhaler canister according to claim 1  
[[28]] comprising as canister an aluminium can which is anodised, lacquer-coated and/or  
plastic coated.

30(currently amended). A metered dose inhaler canister according to claim 29  
wherein the canister which is coated with a fluorocarbon polymer.

31(currently amended). A metered dose inhaler canister according to claim [[28]]  
1 wherein the canister is fitted with a metering valve of metering volume 100  $\mu$ l.

Claim 32(canceled).

33(currently amended). A metered dose inhaler according to claim [[32]] 1  
wherein the channelling device comprises a mouthpiece actuator having an actuator  
orifice of diameter 0.15-0.22mm 0.25mm or less.

34(currently amended). A method of treating respiratory disorders which  
comprises administration by inhalation of an effective amount of a pharmaceutical  
aerosol formulation by means of a metered dose inhaler according to claim 1.

35(currently amended). A metered dose inhaler formulation according to claim  
20 wherein the concentration of solubilising agent in the formulation is 14 to 16% w/w.

36(currently amended). A metered dose inhaler formulation according to claim  
14 wherein the propellant is 1,1,1,2-tetrafluoroethane and a solubilising agent is present  
in the formulation which is ethanol.

Continuation of Appl. No. 10/198,364  
Preliminary Amendment dated: July 31, 2003

37(currently amended). A metered dose inhaler formulation according to claim 15 where in the propellant is 1,1,1,2-tetrafluoroethane and a solubilising agent is present in the formulation which is ethanol.

38(currently amended). A metered dose inhaler formulation according to claim 36 wherein a low volatility component to increase the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler component is present in the formulation which is glycerol at a concentration of 0.5-3% w/w.

Claim 39(canceled).